The Venture Codex

Participated · Seed · Jun 2026

Kimba develops a sleep system that creates a personalized sleep profile for each user and delivers precisely timed olfactory cues using proprietary water-based and plant-derived scent formulations. Its device continuously monitors biometric signals—breathing patterns, movement, heart rate variability and stress indicators—via built-in sensors and integrations with wearables such as WHOOP, Oura, Apple Watch, Fitbit and Garmin. An adaptive AI analyzes this data in real time to tailor scent delivery throughout the night with the goal of improving sleep depth, continuity and recovery without drugs or wakeful interruptions. The company sells pre-orders that include a six-month membership, the Kimba device and a six-month supply of personalized scents for $299. Kimba plans to deploy the new funding to support its commercial launch and accelerate its go-to-market efforts.

Participated · Equity · Feb 2026

Big Health builds evidence-based digital therapeutics, most notably SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder, both of which are among just nine FDA-cleared Digital Mental Health Treatments (DMHTs). Its products are delivered directly to patients or through provider partners, integrate into clinical workflows, and are now eligible for national Medicare reimbursement via newly created G-codes. Backed by more than a decade of real-world use, the company reports serving over 750,000 individuals, with clinical studies showing up to 76 % of SleepioRx users and 71 % of DaylightRx users achieving meaningful symptom improvement. Recent partnerships with health systems such as Henry Ford and Northwell signal accelerating adoption. The company positions its digital solutions as scalable, first-line alternatives to pharmaceuticals, addressing the significant care-access gap for the roughly 20 % of U.S. adults with anxiety disorders and the one-third experiencing chronic insomnia. The fresh capital will be used to deepen provider relationships, expand reimbursement pathways, and reach millions more patients.

Participated · Equity · Aug 2025

Sleep.ai (Consumer Sleep Solutions LLC) offers APIs, SDKs and a consumer app that enable partners to embed clinically validated, AI-driven sleep technology into their products. Its sleep intelligence platform is powered by over 800 million hours of proprietary data, 250+ scientific studies and 90+ publications. The company unifies four capabilities: SleepScore Labs (R&D and validation), the consumer app SleepScore, reimbursed sleep improvement programs such as Dein Schlaf in Germany, and partner-facing APIs/SDKs. Sleep.ai targets partners across digital health, insurance, mental health, women’s health, smart home and hospitality. Led by founder and CEO Colin Lawlor, the company plans to accelerate commercialization and expand partner integrations using the new funding. The product and go-to-market remain focused on scaling AI-powered sleep solutions across health, wellness, insurance, lifestyle and other sectors.

Participated · Series A · Jun 2025

Mosanna Therapeutics is a clinical-stage biotech pioneering a pharmaceutical approach to obstructive sleep apnea with an easily administered nighttime nasal spray, MOS118. MOS118 targets upper airway muscles to restore the body's natural airway reflex and is currently being evaluated in a Phase 1 clinical trial. The company says decreased activity of the natural airway reflex during sleep results in loss of airway patency in OSA patients, and MOS118 aims to correct that dysfunction. The new financing will support advancement of MOS118 through Phase 2 development and will also fund expansion of Mosanna's pipeline. Mosanna appointed David Weber, Ph.D., as President and Chief Executive Officer to lead clinical development and serve on the board. Founded in 2022, the company has offices in Redwood City, California and Basel, Switzerland, and has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High‑Tech Gründerfonds (HTGF). Mosanna Therapeutics is developing MOS-118 (formerly AVE0118), a small-molecule nasal spray acquired from Sanofi, as a targeted treatment for Metabolic Obstructive Sleep Apnea (MOSA). MOSA is characterized by upper-airway obstruction during sleep that reduces blood oxygen, raises cardiac load, and increases cardiovascular mortality risk, and it also causes daytime sleepiness and cognitive problems. The company aims to deliver an effective, well-tolerated precision medicine to patients and notes hundreds of millions are affected globally. Mosanna plans a first Phase 1b clinical trial by end-2023. The recently completed seed financing will fund formulation and manufacturing optimization and regulatory activities to enable that trial. Leadership includes co-founder and CEO Jonathan Talbot and newly appointed Chairman Ben Machielse.

Led · Equity · Dec 2024

Loftie builds technology-driven sleep products and a subscription service, Loftie+, which provides AI-powered, personalized audio content. The company reports over 6,000 Loftie+ subscribers and says new AI-based sleep-improvement features are coming soon. Loftie has hit profitability and maintains proven unit economics. The business plans to bolster top-of-funnel marketing and scale Loftie+ as key growth levers. Management is also developing a Loftie Kids Clock and intends to enter the children's market with screen-free, family-friendly devices and personalized audio. As it enters peak sales season, the company is using a clear roadmap to expand in the digital wellness and personalized sleep sectors.